Tiziana Life Sciences has been granted a significant $4 million NIH award specifically for funding its research in Alzheimer’s Disease by the National Institute on Aging. The NIH award has been awarded to renowned Brigham and Women’s Hospital researcher Dr. Howard Weiner. Such therapy for AD will be studied with nasal anti-CD3. This funding is the most important step for Tiziana, marking the support granted to her to carry out a period of more years of research focused on advancing both preclinical and, eventually, clinical studies of intranasal anti-CD3 as a potential treatment for Alzheimer’s.
Alzheimer’s Disease is the most common type of dementia, affecting over six million Americans alone. Yet, after all these years of research and development, there are still only a few effective treatments. The doctor emphasized the urgency in the establishment of new therapeutic programs to combat this growing health threat. This includes such approaches as anti-CD3 therapy by Tiziana, aiming at modulating the immune system, reducing neuroinflammation, and perhaps slowing the AD progression, which would be an immense relief for millions of patients and their families.
This NIH grant will be the game-changer in the research efforts of Tiziana, especially preclinical studies as well as preparing for the clinical trials that are soon to be conducted. This is considered an affirmation of the potential, which anti-CD3 may offer in its treatment for AD. There is actually much to say, according to Ivor Elrifi, the CEO of Tiziana Life Sciences, that “this is one reason to believe in the innovating nature of our treatment and how it promises to address a very critical unmet need in the treatment of Alzheimer’s disease.”.
In the next months, the company will begin the first-in-human clinical trials using its treatment; this is an essential step to achieve regulatory approval and commercialization. If successful, this therapy will bring into existence a new form of treatment for Alzheimer‘s, which could improve the quality of life in patients affected by that terrible disease, and even change the treatment landscape for AD.
Read More: Click Here
